Question explored with the scientific record
Conversation so far
- 1 Can psma pet scans show false positives
- 2 Which benign conditions most commonly cause PSMA PET uptake?
- 3 Can bph show up as prostate cancer on bi parametric MRIs and PMSA pet scans
Answered on this page ↓
Can bph show up as prostate cancer on bi parametric MRIs and PMSA pet scans
BPH does not typically mimic prostate cancer on PSMA PET, but it can cause false positives on multiparametric MRI.
The retrieved evidence does not directly test whether BPH can mimic prostate cancer on biparametric MRI or PSMA PET. None of the studies here compare imaging findings between BPH and prostate cancer [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28]. The records focus on BPH treatments, drug effects, and PSMA ligand development, not on diagnostic overlap [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28].
What the evidence does show is that PSMA PET tracers are designed to bind prostate-specific membrane antigen, which is overexpressed in prostate cancer cells [14, 15, 19, 20, 23, 27]. BPH tissue does not typically overexpress PSMA, so false positives on PSMA PET from BPH alone are uncommon. However, inflammation or other benign processes can cause PSMA uptake in rare cases.
On MRI, BPH nodules can appear suspicious, especially when they have irregular margins or restricted diffusion. The evidence here does not quantify how often this happens [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28]. A 1995 study found that 8.5% of men clinically diagnosed with BPH actually had prostate cancer on biopsy, showing the two conditions coexist [8].
My call: BPH rarely causes PSMA PET false positives but can produce suspicious MRI findings that require biopsy to distinguish from cancer. Confidence: moderate, limited by the absence of direct comparative imaging studies in this retrieval.
Sources used 28
-
Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?
This study investigates the efficacy and tolerability of a combination therapy of tamsulosin and Serenoa repens compared to each treatment alone in patients with benign prostatic hyperplasia, finding no significant differences in outcomes among the groups.
DOI: 10.2298/vsp110620029a -
Effects of silodosin and tamsulosin on the urethra and cardiovascular system in young and old dogs with benign prostatic hyperplasia
This study investigates the effects of silodosin and tamsulosin on intraurethral pressure and cardiovascular responses in young and old dogs with benign prostatic hyperplasia, finding that silodosin effectively inhibits pressure increases without significant hypotensive effects …
DOI: 10.1016/j.ejphar.2009.04.030 -
Hydroxychloroquine modulates the progression of experimentally induced benign prostatic hyperplasia in rats via targeting EGFR/ERK/STAT3 and AR/FOXO1/TRAIL pathways: computational and in vivo studies
This study investigates the therapeutic potential of hydroxychloroquine in modulating the progression of benign prostatic hyperplasia in rats by targeting key signaling pathways, demonstrating significant reductions in prostate weight, inflammatory markers, and promoting apoptos…
DOI: 10.1038/s41598-025-04267-y -
Association between prostatic resistive index and cardiovascular risk factors in patients with benign prostatic hyperplasia
This study investigates the relationship between prostatic resistive index and cardiovascular risk factors in patients with benign prostatic hyperplasia, finding significant associations with metabolic syndrome and smoking.
DOI: 10.1016/j.kjms.2014.12.008 -
Postoperative PSA and PSA Velocity Identify Presence of Prostate Cancer After Various Surgical Interventions for Benign Prostatic Hyperplasia
This study investigates the ability of postoperative prostate-specific antigen (PSA) levels and PSA velocity to differentiate between patients with prostate cancer and those with benign prostatic hyperplasia after various surgical interventions.
DOI: 10.1016/j.urology.2008.10.062 -
Inhibition effects of chlorogenic acid on benign prostatic hyperplasia in mice
This study investigates the inhibitory effects of chlorogenic acid on testosterone-induced benign prostatic hyperplasia in mice, demonstrating significant reductions in prostate index and related biochemical markers.
DOI: 10.1016/j.ejphar.2017.04.017 -
1571 GENE EXPRESSION PROFILING AND FUNCTIONAL NETWORK ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA MODEL RAT
This study investigates the pharmacokinetics and pharmacodynamics of α1-AR antagonists in patients with benign prostatic hyperplasia (BPH), revealing that receptor binding ability influences therapeutic efficiency over long-term use.
DOI: 10.1016/j.juro.2012.02.1343 -
ASSESSMENT OF SEXTANT BIOPSY OF THE PROSTATE FOR DETECTING CANCER PRIOR TO THERAPY IN PATIENTS CLINICALLY DIAGNOSED AS BENIGN PROSTATIC HYPERPLASIA
This study evaluates the effectiveness of sextant biopsy in detecting prostate cancer in patients clinically diagnosed with benign prostatic hyperplasia, revealing that while it can identify significant tumors, it often misses smaller, insignificant cancers.
DOI: 10.1111/j.1442-2042.1995.tb00435.x -
Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: A short‐term open, randomized multicenter study
This study compares the short-term efficacy and safety of prazosin, terazosin, and tamsulosin in treating lower urinary tract symptoms associated with benign prostatic hyperplasia, finding that terazosin is significantly more effective in improving symptoms compared to tamsulosi…
DOI: 10.1046/j.1442-2042.2000.00175.x -
Effects of Pumpkin Seed in Men with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia in the One-Year, Randomized, Placebo-Controlled GRANU Study
The GRANU study demonstrated that treatment with pumpkin seed significantly improved lower urinary tract symptoms in men with benign prostatic hyperplasia over a one-year period compared to placebo.
DOI: 10.1159/000362903 -
The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality
This study compares the risk of all-cause mortality among men treated for benign prostatic hyperplasia with 5-alpha reductase inhibitors to those treated with alpha-blockers, finding no increased mortality risk associated with 5-ARIs.
DOI: 10.1016/j.urology.2018.05.033 -
A High Risk Factor Score in the Management of Benign Prostatic Hyperplasia
This study evaluates high risk factors in the management of benign prostatic hyperplasia (BPH) using a scoring system that correlates associated medical diseases and complications with patient outcomes, revealing significant insights into postoperative complications and mortalit…
DOI: 10.1111/j.1464-410x.1986.tb09058.x -
A Slow Stream Is Pathophysiologically Related to a Poor Response to α1-Adrenoceptor Therapy in the Treatment of Storage Symptoms Associated With Benign Prostatic Hyperplasia
This study investigates the relationship between urinary stream improvement and the resolution of overactive bladder (OAB) symptoms in patients with benign prostatic hyperplasia (BPH) who did not respond adequately to initial alpha-1 blocker therapy.
DOI: 10.1016/j.urology.2015.03.060 -
Synthesis and preclinical evaluation of an Al18F radiofluorinated bivalent PSMA ligand
The study reports the design, automated synthesis, and preclinical evaluation of an Al-18F labeled bivalent PSMA ligand (18F-Bi-PSMA), demonstrating high tumor uptake, PSMA-specific binding, rapid renal clearance, and superior PET imaging contrast compared with Ga-PSMA-11 and 18…
DOI: 10.1016/j.ejmech.2021.113502 -
PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer
This study presents the first case of whole-body PET/MRI using a 68 Ga-PSMA ligand for the detection of prostate cancer, highlighting its diagnostic accuracy and potential benefits for image-guided biopsy and radiation therapy planning.
DOI: 10.1007/s00259-013-2489-5 -
The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model
A simulation study using a whole-body PBPK model investigated how ligand amount, affinity, and internalization of PSMA-targeted ligands influence imaging activity concentrations and therapy-absorbed doses in 13 virtual patients, revealing that high affinity mainly enhances thera…
DOI: 10.1038/s41598-019-56603-8 -
Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors
This study presents a new class of trifunctional ligands for prostate cancer targeting that significantly improves tumor uptake and retention compared to existing therapies, potentially enhancing the efficacy of radioligand therapy.
DOI: 10.1007/s00259-018-4004-5 -
Effect of Chelators on the Pharmacokinetics of 99m Tc-Labeled Imaging Agents for the Prostate-Specific Membrane Antigen (PSMA)
12 newly synthesized 99mTc-labeled PSMA-targeted radioligands with diverse chelators were compared across Tc(I) tricarbonyl, Tc(V)-oxo, and HYNIC cores in PSMA-positive PC3 PIP and PSMA-negative PC3 flu xenografts in mice, revealing that chelator design profoundly influences pha…
DOI: 10.1021/jm400823w -
Molecular targets and the emerging role of copper radionuclides in prostate cancer theranostics
This review surveys copper-radioisotope–based radiopharmaceuticals for prostate cancer theranostics, detailing copper isotopes (Cu-61, Cu-64, Cu-67), chelation chemistries, molecular targets (PSMA, GRPR, and others), preclinical/clinical data, production routes, translational ch…
DOI: 10.1186/s13550-025-01325-4 -
Synthesis and Evaluation of 68 Ga- and 177 Lu-Labeled ( R )- vs ( S )-DOTAGA Prostate-Specific Membrane Antigen-Targeting Derivatives
The study reports the synthesis and comparative evaluation of (R)- and (S)-DOTAGA–PSMA derivatives labeled with 68Ga for PET imaging and 177Lu for radionuclide therapy, showing similar PSMA targeting between isomers but notable stereo-dependent differences in Lu-177 labeling kin…
DOI: 10.1021/acs.molpharmaceut.0c00777 -
Polypeptide-Based Molecular Platform and Its Docetaxel/Sulfo-Cy5-Containing Conjugate for Targeted Delivery to Prostate Specific Membrane Antigen
The study designed a polypeptide-based molecular platform (EuK-based PSMA vector) and demonstrated a bimodal theranostic conjugate with docetaxel and Sulfo-Cy5, showing selective uptake and cytotoxicity in PSMA-expressing prostate cancer cell lines and illustrating a comparative…
DOI: 10.3390/molecules25245784 -
The efficiency of 18 F labelling of a prostate specific membrane antigen ligand via strain-promoted azide–alkyne reaction: reaction speed versus hydrophilicity
This study compares the efficiency of two methods for labeling prostate-specific membrane antigen ligands with fluorine-18 for positron emission tomography (PET) imaging, revealing that while one method is faster, the other provides significantly better tumor uptake and contrast.
DOI: 10.1039/c8cc03999b -
Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy
Intraindividual comparisons of three 18F-labeled PSMA tracers (DCFPyL, PSMA-1007, JK-PSMA-7) against the standard 68Ga-PSMA-11 in 41 prostate cancer patients with biochemical recurrence reveal tracer-specific biodistribution differences that alter liver, parotid gland, and splee…
DOI: 10.1186/s13550-024-01190-7 -
Surface receptor‐mediated targeted drug delivery systems for enhanced cancer treatment: A state‐of‐the‐art review
A comprehensive state-of-the-art review of surface receptor–mediated, nanoengineered drug-delivery systems for cancer therapy, detailing receptor targets, ligands, carrier types, preclinical evidence, and the challenges/limitations for clinical translation.
DOI: 10.1002/ddr.21758 -
Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer
The study demonstrates that prostate-specific membrane antigen (PSMA) is present on tumor neovasculature and TNBC cells, and that radiolabeled PSMA ligands can target TNBC both in vitro and in vivo, supporting PSMA-directed endogenous radioligand therapy for triple-negative brea…
DOI: 10.1186/s13058-019-1205-1 -
Optimizing Liposomal Drug Delivery for Enhanced Efficacy in Skin Cancer Treatment: A Comprehensive Experimental Investigation
Targeted liposomal drug delivery shows potential for enhanced skin cancer treatment through lipid optimization and surface ligands in in vitro studies, but conclusions rely on simulated data and lack in vivo validation.
DOI: 10.22270/jddt.v14i6.6566 -
The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions
This study evaluates the biodistribution, radiation dosimetry, and tumor detection capabilities of the novel theranostic PSMA-ligand PSMA-617 in patients with prostate cancer using PET/CT imaging.
DOI: 10.2967/jnumed.115.161299 -
In vivo self-assembled nano-PROTAC for the dual degradation of AR and HSP90 to overcome castration-resistant prostate cancer resistance
A PSMA-targeted self-assembling nano-PROTAC (Psa-AR) achieves proximity-induced degradation of AR and HSP90 (including AR-V7), enabling tumor-selective delivery and durable, dual-protein degradation that markedly suppresses AR-driven prostate cancer in vitro and in vivo with lim…
DOI: 10.1038/s41392-025-02444-z